Skip to main content
. 2016 Jun 28;8(2):6165. doi: 10.4081/rt.2016.6165

Table 1.

Patient and tumor characteristics by site of presentation.

Characteristic Patient and tumor characteristics by site*
Neck (n=16) Paranasal sinus (n=3) Scalp/face (n=27) Supraclavicular (n=2) Total (N=48)
Age at diagnosis, y
   Median 48.8 74.4 70.0 27.6 68.5
   Range (19.1-85.6) (41.8-82.6) (23.5-86.9) (25.9-29.2) (19.1-86.9)
Sex
   Female 4 (25.0) 1 (33.3) 9 (33.3) 0 (0.0) 14 (29.2)
   Male 12 (75.0) 2 (66.7) 18 (66.6) 2 (100.0) 34 (70.8)
Presentation
   Recurrent 5 (31.3) 0 (0.0) 4 (14.8) 1 (50.0) 10 (20.8)
   Primary 11 (68.8) 3 (100.0) 23 (85.2) 1 (50.0) 38 (79.2)
Histologic finding
   DFSP 1 (6.3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.1)
   Leiomyosarcoma 2 (12.5) 0 (0.0) 3 (11.1) 0 (0.0) 5 (10.4)
   MPNST 0 (0.0) 0 (0.0) 1 (3.7) 0 (0.0) 1 (2.1)
   MFH/UPS 3 (18.8) 0 (0.0) 4 (14.8) 2 (100.0) 9 (18.8)
   Spindle cell 2 (12.5) 0 (0.0) 2 (7.4) 0 (0.0) 4 (8.3)
   Synovial sarcoma 5 (31.3) 0 (0.0) 1 (3.7) 0 (0.0) 6 (12.5)
   Angiosarcoma 0 (0.0) 1 (25.0) 13 (48.1) 0 (0.0) 14 (29.2)
   Liposarcoma 1 (6.3) 0 (0.0) 2 (7.4) 0 (0.0) 3 (6.3)
   Other° 2 (12.5) 1 (25.0) 0 (0.0) 0 (0.0) 3 (6.3)
   Hemangiopericytoma 0 (0.0) 1 (25.0) 1 (3.7) 0 (0.0) 2 (4.2)
   Rhabdomyosarcoma 0 (0.0) 1 (25.0) 0 (0.0) 0 (0.0) 1 (2.1)
Grade
   Low 2 (12.5) 0 (0.0) 4 (14.8) 0 (0.0) 6(12.5)
   High 7 (43.8) 1 (33.3) 18 (66.8) 2 (100.0) 28 (58.3)
   Not available 7 (43.8) 2 (66.7) 5 (18.5) 0 (0.0) 14 (29.1)
Size, cm
   ≤5 11 (68.8) 3 (100.0) 17 (63.0) 2 (100.0) 33 (68.8)
   >5 5 (31.3) 0 (0.0) 10 (37.0) 0 (0.0) 15 (31.2)
Depth
   Superficial 2 (12.5) 0 (0.0) 16 (59.3) 1 (50.0) 19 (39.6)
   Deep 14 (87.5) 3 (100.0) 11 (40.3) 1 (50.0) 29 (60.4)

DFSP, dermatofibrosarcoma protuberans; MFH, malignant fibrous histiocytoma; MPNST, malignant peripheral nerve sheath tumor; UPS, unclassified pleomorphic sarcoma.

*Values are presented as number and percentage of patients unless specified otherwise.

°Other histologic findings include interdigitating dendritic cell sarcoma, chordoma, and hemangioendothelioma.